1. |
Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J].CA Cancer J Clin, 2013, 63(1):11-30.
|
2. |
Coleman RE, Rubens RD.The clinical course of bone metastases from breast cancer[J].Br J Cancer, 1987, 55(1):61-66.
|
3. |
Singletary SE, Walsh G, Vauthey JN, et al.A role for curative surgery in the treatment of selected patients with metastatic breast cancer[J].Oncologist, 2003, 8(3):241-251.
|
4. |
Mundy GR.Metastasis to bone:causes, consequences and therapeutic opportunities[J].Nat Rev Cancer, 2002, 2(8):584-593.
|
5. |
邵志敏,沈镇宙,徐兵河,等.乳腺肿瘤学[M].上海:复旦大学出版社, 2013:777-784.
|
6. |
Mansi JL, Gogas H, Bliss JM, et al.Outcome of primary-breastcancer patients with micrometastases:a long-term follow-up study[J].Lancet, 1999, 354(9174):197-202.
|
7. |
Roodman GD.Mechanisms of bone metastasis[J].N Engl J Med, 2004, 350(16):1655-1664.
|
8. |
Coleman RE.Metastatic bone disease:clinical features, pathophysiology and treatment strategies[J].Cancer Treat Rev, 2001, 27(3):165-176.
|
9. |
Schenk R, Eggli P, Fleisch H, et al.Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat[J].Calcif Tissue Int, 1986, 38(6):342-349.
|
10. |
Russell RG, Xia Z, Dunford JE, et al.Bisphosphonates:an update on mechanisms of action and how these relate to clinical efficacy[J].Ann N Y Acad Sci, 2007, 1117(11):209-257.
|
11. |
US Preventive Services Task Force.Screening for breast cancer:U.S.Preventive Services Task Force recommendation statement[J].Ann Intern Med, 2009, 151(10):716-726.
|
12. |
Li GL, Chen WQ.Representativeness of population-based cancer registration in China-comparison of urban and rural areas[J].Asian Pac J Cancer Prev, 2009, 10(4):559-564.
|
13. |
Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol, 2011, 22(8):1736-1747.
|
14. |
孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生出版社, 2007:920-921.
|
15. |
Moreau J, Anderson KM, Mauney JR, et al.Studies of osteotropism on both sides of the breast cancer-bone interaction[J].Ann N Y Acad Sci, 2007, 1117(11):328-344.
|
16. |
Paget S.The distribution of secondary growths in cancer of the breast.1889[J].Cancer Metastasis Rev, 1989, 8(2):98-101.
|
17. |
Cawthorn TR, Amir E, Broom R, et al.Mechanisms and pathways of bone metastasis:challenges and pitfalls of performing molecular research on patient samples[J].Clin Exp Metastasis, 2009, 26(8):935-943.
|
18. |
Psaila B, Lyden D.The metastatic niche:adapting the foreign soil[J].Nat Rev Cancer, 2009, 9(4):285-293.
|
19. |
Gnant M, Mlineritsch B, Stoeger H, et al.Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with earlystage breast cancer:62-month follow-up from the ABCSG-12 randomised trial[J].Lancet Oncol, 2011, 12(7):631-641.
|
20. |
Bundred NJ, Campbell ID, Davidson N, et al.Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole:ZO-FAST Study results[J].Cancer, 2008, 112(5):1001-1010.
|
21. |
AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal>5 years[J].Oncology (Williston Park), 2011, 25(12):1212-1213.
|
22. |
Harris JR, Lippman ME, Morrow M著.王永胜,吴炅,于金明,等译[M].第4版.济南:山东科学技术出版社, 2012:1543-1555.
|
23. |
洪婷婷,华东.含氮双磷酸盐的抗肿瘤作用[J].国际肿瘤学杂志, 2011, 38(4):257-258.
|